Canagliflozin

Canagliflozin is a prescription drug best known as a diabetes medication. It has drawn attention in longevity circles for a separate reason: it extended lifespan in male mice through the National Institute on Aging's Interventions Testing Program (ITP), one of the most rigorous preclinical longevity screens in existence.

What the mouse data show

The ITP result for canagliflozin is specific and important to read carefully. Male mice showed significant lifespan extension, confirmed across multiple independent ITP sites [1]. Female mice, tested at the same dose, showed no benefit. The reason appears to be pharmacokinetic: female mice reach blood concentrations roughly 20-fold higher than males at an identical dose [1]. Verhoeven's analysis suggests this mirrors the pattern seen with 17α-estradiol, another ITP compound where sex-specific dosing changed the outcome entirely [2]. A lower dose in females is currently under retesting.

This is preclinical data only. No human longevity trial exists for canagliflozin in non-diabetic adults, and the mouse results do not substitute for one.

Human cardiovascular evidence, real, but different

Canagliflozin does have substantial human trial data, though not for longevity. Large cardiovascular outcome trials in people with type 2 diabetes, including CANVAS and CREDENCE, demonstrated meaningful reductions in heart failure hospitalization and kidney disease progression. This evidence applies to people with established diabetes and cardiometabolic disease; it does not establish whether canagliflozin extends healthspan or lifespan in metabolically healthy individuals. The cardiovascular data supports the drug's safety profile and points toward plausible cardiometabolic mechanisms, but the longevity claim remains preclinical.

How it works

Canagliflozin blocks SGLT2, a transporter in the kidney that normally reclaims glucose from urine back into the bloodstream. Blocking it forces glucose out through urination, lowering blood glucose and blunting insulin spikes. Verhoeven's analysis notes secondary effects may include a mild caloric deficit, modest elevation of ketone bodies, and AMPK activation [2]. Peter Attia has described the mechanism as meaningfully distinct from metformin's: canagliflozin does not inhibit mitochondrial complex I, the property of metformin that has raised concerns about blunting aerobic exercise adaptation [3].

Peter Attia's personal use, and what that does and doesn't mean

Attia has publicly discussed switching from metformin to an SGLT2 inhibitor after stopping metformin due to concerns about resting lactate and impaired zone-2 training adaptation [3]. His reasoning: targeting glucose and insulin signaling without the mitochondrial inhibition that may interfere with endurance exercise physiology [3]. This is a named expert's personal decision, not a controlled trial result. Attia is a prominent longevity physician with a large public platform and his views carry influence; readers should weigh that against the absence of RCT evidence backing his choice for longevity purposes specifically.

Current status

Canagliflozin falls into a category LampHill calls "preliminary (preclinical only, males)": a confirmed ITP hit in one sex, solid cardiovascular outcome data in a specific patient population, a mechanistically coherent rationale, and no human longevity data. The sex-dosing question remains open and is actively under investigation.

Where the evidence is contested

The central dispute is whether the ITP male lifespan result translates to anything meaningful in humans, and whether cardiovascular outcome data in diabetics says anything about longevity in non-diabetics. Verhoeven's analysis positions the ITP result as a genuine signal and notes the mechanistic distinction from metformin as a practical advantage for physically active users [2]. The counterpoint, noted in the wiki's own framing, is that preclinical lifespan extension in mice has repeatedly failed to replicate in humans. Cardiovascular benefit in a high-risk disease population is not a proxy for longevity benefit in healthy adults. No source on this page resolves that gap, because no human data yet exists to resolve it.

References

1. Miller et al. 2020 (JCI Insight) — ITP Canagliflozin; male-specific (+14%); female blood conc. ~20-fold higher (not 3–10× as cited by Miller);… · PubMed 32990681
2. Attia ep281 — ITP longevity drugs (Rich Miller)
3. Attia ep270 — Metformin journal club (Attia + Huberman)